Your browser is no longer supported. Please, upgrade your browser.
Settings
PTI Proteostasis Therapeutics, Inc. daily Stock Chart
PTI [NASD]
Proteostasis Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.81 Insider Own20.43% Shs Outstand35.00M Perf Week10.78%
Market Cap89.95M Forward P/E- EPS next Y-1.70 Insider Trans0.00% Shs Float29.20M Perf Month4.05%
Income-53.90M PEG- EPS next Q-0.43 Inst Own65.20% Short Float8.70% Perf Quarter-13.47%
Sales5.00M P/S17.99 EPS this Y-13.60% Inst Trans-2.16% Short Ratio13.78 Perf Half Y-49.11%
Book/sh1.56 P/B1.65 EPS next Y-9.00% ROA-71.60% Target Price13.50 Perf Year25.98%
Cash/sh1.74 P/C1.48 EPS next 5Y- ROE-96.40% 52W Range1.41 - 8.61 Perf YTD-55.92%
Dividend- P/FCF- EPS past 5Y- ROI-87.20% 52W High-70.15% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin- 52W Low82.27% ATR0.14
Employees50 Current Ratio6.70 Sales Q/Q-27.30% Oper. Margin- RSI (14)56.74 Volatility7.03% 5.89%
OptionableYes Debt/Eq0.00 EPS Q/Q36.50% Profit Margin- Rel Volume0.39 Prev Close2.51
ShortableYes LT Debt/Eq0.00 EarningsSep 14 AMC Payout- Avg Volume184.30K Price2.57
Recom1.80 SMA203.86% SMA503.02% SMA200-33.87% Volume72,096 Change2.39%
Dec-12-17Reiterated Robert W. Baird Outperform $13 → $25
Apr-18-16Initiated Guggenheim Neutral
Mar-07-16Initiated Robert W. Baird Outperform $13
Mar-07-16Initiated RBC Capital Mkts Outperform $20
Mar-07-16Initiated Leerink Partners Outperform
Mar-07-16Initiated H.C. Wainwright Buy $15
Jun-25-18 07:00AM  Proteostasis Added to the Russell 3000® Index PR Newswire
Jun-08-18 08:00AM  Todays Research Reports on Stocks to Watch: Proteostasis Therapeutics and Ophthotech Corporation ACCESSWIRE
07:50AM  Proteostasis Therapeutics (PTI) Enters Oversold Territory Zacks
07:35AM  Analysis: Positioning to Benefit within Proteostasis Therapeutics, Yum China, Pretium Resources, Lexington Realty Trust, AngloGold Ashanti, and New Gold Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Jun-07-18 04:52PM  More Data Needed On Proteostasis Therapeutics' Cystic Fibrosis Candidate, RBC Says In Downgrade Benzinga -38.16%
Jun-06-18 04:05PM  Proteostasis Announces Positive Data from Ongoing Phase 1 Study of PTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy PR Newswire
Jun-04-18 07:20AM  Initiating Free Research Reports on Pulmatrix and Three Other Biotech Equities ACCESSWIRE
Jun-01-18 07:00AM  Proteostasis Announces Presentations at the 41st European Cystic Fibrosis Society Conference PR Newswire
May-31-18 07:00AM  Proteostasis Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference PR Newswire
May-08-18 07:00AM  Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis PR Newswire
Apr-24-18 12:32PM  Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping World Holdings, Inc., Finish Line, Inc., Myriad Genetics, Inc., Proteostasis Therapeutics, Inc., Under Armour, Inc. and United Community Bancorp PR Newswire
Apr-17-18 07:10AM  Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko Therapy PR Newswire
Apr-16-18 08:40AM  Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock? Zacks
Apr-06-18 07:00AM  Blog Exposure - FDA Granted Fast Track Designation to Proteostasis Therapeutics Triple Combination Program for Cystic Fibrosis ACCESSWIRE
Apr-04-18 08:29AM  Proteostasis shares surge 12% on FDA 'fast track' designation for cystic fibrosis treatment MarketWatch +6.52%
06:00AM  Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis PR Newswire
Apr-03-18 07:30PM  PTI INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors Business Wire -5.12%
Mar-27-18 08:20AM  Consolidated Research: 2018 Summary Expectations for TE Connectivity, CNH Industrial N.V., Proteostasis Therapeutics, Qudian Inc. Sponsored ADR, Arcos Dorados, and Crescent Point Energy Fundamental Analysis, Key Performance Indications GlobeNewswire
Mar-22-18 04:47PM  PROTEOSTASIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Proteostasis Therapeutics, Inc. To Contact The Firm PR Newswire
10:30AM  Glancy Prongay & Murray LLP Continues Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI) Business Wire
Mar-21-18 04:29PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI) Business Wire +6.01%
04:06PM  Bragar Eagel & Squire, P.C. is Investigating Proteostasis Therapeutics, Inc. (PTI) on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
12:30PM  Scott+Scott Attorneys at Law LLP Announces Investigation into Proteostasis Therapeutics, Inc. (PTI) PR Newswire
09:06AM  Proteostasis won't complete public offering after short report; shares rise 14% MarketWatch
08:03AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
06:58AM  ICYMI: Proteostasis Bear Call, eSports, Oracle's Q3, Roku Interview Benzinga
Mar-20-18 07:59PM  Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions PR Newswire -26.18%
01:32PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proteostasis Therapeutics, Inc. - PTI PR Newswire
12:51PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Proteostasis Therapeutics, Inc. (PTI) PR Newswire
11:41AM  Biotech short seller eviscerates Proteostasis in new report, dinging shares American City Business Journals
10:19AM  Proteostasis Therapeutics shares tank 18% after Kerrisdale Capital puts out short report MarketWatch
08:02AM  Benzinga Pro's 6 Stocks To Watch Today Benzinga
Mar-19-18 04:01PM  Proteostasis Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Mar-16-18 02:33PM  The Week Ahead In Biotech: Earnings, PDUFA Dates And More Benzinga
10:59AM  Baird: Prospects For Proteostasis Therapeutics' PTI-428 Are Not Priced Into The Stock Benzinga
08:37AM  Proteostasis Therapeutics (PTI) Looks Good: Stock Adds 8% in Session Zacks
Mar-15-18 12:06PM  Did Insiders Buy On Proteostasis Therapeutics Incs (NASDAQ:PTI) Price Volatility? Simply Wall St. +8.01%
08:49AM  Proteostasis stock rises 22% on FDA designation, smaller-than-expected Q4 loss MarketWatch
08:25AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
05:03AM  Proteostasis reports 4Q loss Associated Press
Mar-14-18 05:29PM  Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Business Update GlobeNewswire
04:30PM  Proteostasis Therapeutics Announces FDA Grants Orphan Drug Designation for PTI-428 in Cystic Fibrosis GlobeNewswire
Mar-13-18 01:20PM  Proteostasis Therapeutics Inc (PTI) Soars on Cystic Fibrosis Approval InvestorPlace +54.11%
10:16AM  Proteostasis's stock rockets on heavy volume after BTD granted MarketWatch
08:12AM  Benzinga Pro's 5 Stock To Watch Today Benzinga
Mar-12-18 04:05PM  Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis GlobeNewswire
Mar-07-18 07:00AM  Proteostasis Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-08-18 07:00AM  Proteostasis Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference GlobeNewswire -6.79%
Jan-08-18 07:00AM  Proteostasis Proprietary Triple Combination Therapy Study Protocol Receives Endorsement and High Strategic Fit Score from the Largest Cystic Fibrosis Patient Advocacy Groups in the U.S. and Europe GlobeNewswire -6.87%
Dec-26-17 12:00PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : December 26, 2017 Capital Cube +5.76%
Dec-21-17 04:50PM  Proteostasis Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Dec-19-17 09:15AM  Proteostasis Therapeutics Inc (PTI) President and CEO Meenu Chhabra Bought $200,000 of Shares GuruFocus.com +12.30%
Dec-15-17 10:00AM  Proteostasis Therapeutics, Inc. (Nasdaq:PTI) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire +6.40%
Dec-13-17 09:24AM  Proteostasis Stock Surges on Positive Data From CF Studies Zacks -10.91%
08:05AM  Proteostasis Soars on News of Positive Trial Results, Baird Says Outperform ACCESSWIRE
Dec-12-17 04:24PM  Proteostasis Therapeutics shares down 8% after proposed share offering MarketWatch +161.28%
02:00PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : December 12, 2017 Capital Cube
01:11PM  Proteostasis Therapeutics Inc (PTI) Is Blasting Off 165% Following Three Clinical Wins in Cystic Fibrosis SmarterAnalyst
07:29AM  Proteostasis Therapeutics' stock nearly doubles on heavy volume after positive trial results MarketWatch
Dec-11-17 04:21PM  Proteostasis Therapeutics Announces Positive Clinical Results from Studies of PTI-428, PTI-801 and PTI-808 in Healthy Volunteers and Patients with Cystic Fibrosis GlobeNewswire
Nov-29-17 08:49AM  Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube +32.14%
Nov-16-17 05:14AM  Proteostasis reports 3Q loss Associated Press
Nov-14-17 05:40PM  Proteostasis Therapeutics Reports Third Quarter 2017 Results and Provides CF Portfolio Update GlobeNewswire
Nov-06-17 12:21PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : November 6, 2017 Capital Cube
Oct-31-17 04:05PM  Proteostasis Therapeutics Focuses on Research and Development of CF Drug Candidates and Astellas Pharma Collaboration Programs GlobeNewswire
Oct-26-17 10:44AM  ETFs with exposure to Proteostasis Therapeutics, Inc. : October 26, 2017 Capital Cube
Oct-16-17 09:58AM  ETFs with exposure to Proteostasis Therapeutics, Inc. : October 16, 2017 Capital Cube
Oct-11-17 09:54AM  Is Proteostasis Therapeutics Inc (PTI) Thriving Or Barely Surviving In The Healthcare Sector? Simply Wall St. +6.28%
Aug-31-17 08:22PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-25-17 11:59AM  Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Jul-31-17 04:16PM  Proteostasis Therapeutics Announces Progression of PTI-428 and PTI-801 to Longer Duration Studies in CF Subjects GlobeNewswire -7.49%
04:15PM  Proteostasis Appoints Helen M. Boudreau as Chief Financial Officer GlobeNewswire
Jun-29-17 07:00AM  Proteostasis Therapeutics Reports Preliminary Data from Phase 1 Study of PTI-428 in Patients with Cystic Fibrosis GlobeNewswire
Jun-23-17 07:00AM  Proteostasis Therapeutics Files Investigational New Drug Application for PTI-808, Cystic Fibrosis Potentiator GlobeNewswire
Jun-07-17 07:00AM  Proteostasis Therapeutics Announces Clinical and Regulatory Progress Across Pipeline Programs GlobeNewswire -5.90%
Jun-05-17 02:41PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : June 5, 2017 Capital Cube
Jun-02-17 10:07AM  Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017 Capital Cube
May-15-17 04:25PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : May 15, 2017 Capital Cube -8.48%
May-01-17 04:19PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : May 1, 2017 Capital Cube
02:52PM  What's in Store for Juno Therapeutics (JUNO) in Q1 Earnings? Zacks
Apr-20-17 02:27PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : April 20, 2017 Capital Cube
Apr-10-17 01:55PM  ETFs with exposure to Proteostasis Therapeutics, Inc. : April 10, 2017 Capital Cube
Apr-07-17 03:00PM  Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: Q4, 2016 By the Numbers : April 7, 2017 Capital Cube
12:29PM  Proteostasis Therapeutics, Inc. :PTI-US: Earnings Analysis: 2016 By the Numbers : April 7, 2017 Capital Cube
Mar-30-17 04:46PM  PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosu
04:46PM  Proteostasis reports 4Q loss Associated Press
04:30PM  Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update GlobeNewswire
04:24PM  PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
Mar-06-17 09:28AM  Proteostasis Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTI-US : March 6, 2017 Capital Cube
09:28AM  Proteostasis Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : PTI-US : March 6, 2017
Feb-01-17 04:54PM  PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jan-27-17 02:00PM  Proteostasis Therapeutics, Inc. Value Analysis (NASDAQ:PTI) : January 27, 2017 Capital Cube
02:00PM  Proteostasis Therapeutics, Inc. Value Analysis (NASDAQ:PTI) : January 27, 2017
Jan-26-17 07:45AM  Proteostasis Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTI-US : January 26, 2017 Capital Cube
07:45AM  Proteostasis Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : PTI-US : January 26, 2017
Jan-09-17 08:53AM  PROTEOSTASIS THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Dec-29-16 02:55PM  This Boston law firm won the most IPO work locally in 2016 at bizjournals.com
02:55PM  This Boston law firm won the most IPO work locally in 2016 American City Business Journals
Dec-10-16 06:16PM  Is Proteostasis Therapeutics Inc (PTI) a Good Stock to Buy? Insider Monkey
06:16PM  Is Proteostasis Therapeutics Inc (PTI) a Good Stock to Buy? at Insider Monkey
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chhabra MeenuPresident and CEODec 18Buy5.0040,000200,00050,218Dec 19 08:47 AM
Kelly Jeffery W.DirectorDec 18Buy5.004,00020,000102,411Dec 19 08:46 AM
BERGER FRANKLIN MDirectorDec 18Buy5.0060,000300,000266,162Dec 19 08:46 AM
BARRETT M JAMESDirectorDec 18Buy5.002,000,00010,000,0005,554,610Dec 19 08:56 AM
New Enterprise Associates 12, 10% OwnerDec 18Buy5.002,000,00010,000,0005,554,610Dec 19 08:55 AM